Companies · Biotechnology

Celularity Inc.

WARREN · Biotechnology

Diligence memoA one-page analyst read on Celularity Inc. — recommendation, valuation, rhythm, risks.
$117.7M
Total raised · real
2
Rounds
1.9×
Latest step-up
Top 9%
Sector rank · raised
Series C
Latest stage · inferred · Mon May 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Celularity Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.55× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Celularity Inc. is one of 4291 Biotechnology companies tracked from WARREN. By capital raised it ranks among the largest (ahead of 92% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2016
Year incorporated
2018-05-07
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2017-08-15 Raised $40M (real) Modeled valuation $1.6B (est)$40M$1.6BSeries C2017Series C · 2018-05-07 Raised $78M (real) Modeled valuation $3.2B (est)$78M$3.2BSeries C2018+$78MCumulative $118M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$40.0M · 2017
Series C extension$77.7M · 2018

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.

Modeled valuation trajectory
$3.2B
Base estimate est.
$240.4M
Conservative case
$8.4B
Upside case
$518.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series C · modeled $1.6B · 2017-08-152017Series C · modeled $3.2B · 2018-05-072018
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
8.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$162.2M/yr
Capital velocity
8.9 yr
On record since
2017
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 16× above median
This company$117.7M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.7× above median
This company$77.7M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 50× above median
This company$3.2B
Sector median$64.2M

Raised more than 92% of sector peers (real $). Modeled value above 97% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 41.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Genesis Biopharma, Inc · Series C Raised $131.5M · modeled $4.1B (est)Alder Biopharmaceuticals Inc · Series C Raised $100.0M · modeled $4.1B (est)Ideaya Biosciences, Inc. · Series C Raised $111.4M · modeled $3.9B (est)Stoke Therapeutics, Inc. · Series C Raised $90.8M · modeled $3.7B (est)4D Molecular Therapeutics Inc · Series C Raised $108.6M · modeled $3.7B (est)Sutro Biopharma Inc · Series C Raised $85.4M · modeled $3.5B (est)Evelo Biosciences, Inc. · Series C Raised $131.5M · modeled $3.3B (est)Codiak BioSciences, Inc. · Series C Raised $107.5M · modeled $3.1B (est)Arcturus Therapeutics Ltd. · Series C Raised $67.8M · modeled $2.8B (est)Celldex Therapeutics, Inc. · Series C Raised $64.5M · modeled $2.6B (est)Micell Technologies Inc · Series C Raised $62.1M · modeled $2.5B (est)Celularity Inc. (this company) Raised $117.7M · modeled $3.2B (est)Celularity Inc.
CompanyStageRaised · realValue · estvs peer med.
Genesis Biopharma, IncSeries C$131.5M$4.1B2.00×
Alder Biopharmaceuticals IncSeries C$100.0M$4.1B2.00×
Ideaya Biosciences, Inc.Series C$111.4M$3.9B1.88×
Stoke Therapeutics, Inc.Series C$90.8M$3.7B1.80×
4D Molecular Therapeutics IncSeries C$108.6M$3.7B1.80×
Sutro Biopharma IncSeries C$85.4M$3.5B1.71×
Evelo Biosciences, Inc.Series C$131.5M$3.3B1.63×
Celularity Inc. this companySeries C$117.7M$3.2B1.55×
Codiak BioSciences, Inc.Series C$107.5M$3.1B1.53×
Arcturus Therapeutics Ltd.Series C$67.8M$2.8B1.36×
Celldex Therapeutics, Inc.Series C$64.5M$2.6B1.25×
Micell Technologies IncSeries C$62.1M$2.5B1.24×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$40.0M2017-08-15$266.7M$1.6B90%
Series C$77.7M2018-05-07$518.0M$3.2B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$40.0M2017-08-15
    • First recorded raise — entered as Series C.
    • 16 investors on this round.
  2. Series C$77.7M2018-05-07
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 5 investors on this round.
Intelligence
2019 ~Q1
Modeled next raise · ~9mo cadence
$150.9M
Modeled next size est.range $98.1M$241.5M
1.9×
Last step-up
$162.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
PETER DIAMANDIS9 other2018-05
John Sculley5 other2018-05
Henry Ji4 other2018-05
Robert Hariri4 other2017-08
Timothy Smith4 other2017-08
Andrew Pecora3 other2018-05
CARLOS RAMIREZ3 other2018-05
Tim Smith3 other2018-05
Andrew Von Eschenbach2 other2018-05
Jaisim Shah2 other2018-05
John R. Haines1 other2017-08
Kok Thay Lim1 other2018-05
Peter R. Diamandis1 other2017-08
Andrew R. Pecora2017-08
Andrew R. Von Eschenbach2017-08
Beth R. Steinbrenner2017-08
Beth Steinbrenner2018-05
Bill Maris2018-05
Bill R. Maris2017-08
Bill Waller2018-05
Curtis Quigley2018-05
Curtis R. Quigley2017-08
David Lemus2018-05
David R. Deming2017-08
Registry & provenance

Celularity Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1716918
SEC CIK
2016
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Scilex Holding CoBiotechnologySeries D+$104.6M$19.5Mnetwork2 shared operators · same sector
Aardvark Therapeutics, Inc.BiotechnologySeries C$103.1M$807.3Mnetwork1 shared operator · same sector · same stage
Celularity IncBiotechnologySeries B$41.8M$8.1Mnetwork2 shared operators · same sector
Civitas Therapeutics, Inc.BiotechnologySeries C$117.8M$2.3Bsame sector · same stage
Adicet Bio, Inc.BiotechnologySeries C$116.8M$3.3Bsame sector · same stage
Dicerna Pharmaceuticals IncBiotechnologySeries C$118.9M$2.5Bsame sector · same stage
Magenta Therapeutics, Inc.BiotechnologySeries C$116.0M$2.1Bsame sector · same stage
Vineti, Inc.BiotechnologySeries C$115.7M$2.8Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Celularity IncBiotechnologySeries B$8.1M100%
Celcuity Inc.BiotechnologySeries D+$691.3M87%
Cerecin Inc.BiotechnologySeries C$34.1M86%
Cerium Pharmaceuticals, Inc.BiotechnologySeries A$193.1M86%
Ceres Nanosciences, Inc.BiotechnologySeries A$63.5M86%
CeraRoot USA IncBiotechnologyPre-Seed$1.6M86%
CereVasc, Inc.BiotechnologySeries A$399.6M86%
Celsense IncBiotechnologyPre-Seed$27.6M86%
Frequently asked
How much funding has Celularity Inc. raised?
Celularity Inc. has raised approximately $117.7M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Celularity Inc.'s estimated valuation?
Provath's modeled valuation for Celularity Inc. is approximately $3.2B (modeled range $240.4M–$8.4B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Celularity Inc. at?
Celularity Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Mon May 07.
What does Celularity Inc. do and where is it based?
Celularity Inc. operates in the Biotechnology sector, based in WARREN.
Explore related

See where Celularity Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Celularity Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.